trial

Treatment of Cognitive Impairment in Men With Schizophrenia (MK5757-005)(COMPLETED)

NCTId NCT00848484
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 54 (actual)
Sponsored by Merck Sharp & Dohme LLC
Primary completion 2009-06
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
54 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Double
Start
2008-10
Primary completion
2009-06
Eligibility
MALE · 21 Years · 55 Years

Interventions & indications

Drugs
MK5757

Sponsors

Merck Sharp & Dohme LLCLead Sponsor

Sites

0 total

Linked catalysts

1
Treatment of Cognitive Impairment in Men With Schizophrenia (MK5757-005)(COMPLET — primary completion2009-06

Facts & assertions

4 sourced
Enrollment
54
Phase
PHASE2
Primary Completion Date
2009-06
Status
COMPLETED
relationships
The graph out of here
drug
MK5757
drug
lead_sponsor
Merck Sharp & Dohme LLC
company
indication
Schizophrenia
indication
Schizophrenia
indication